Home Newsfeeds Wedbush Downgrades Allbirds to Neutral, Announces $3 Price Target

Wedbush Downgrades Allbirds to Neutral, Announces $3 Price Target

Wedbush analyst Tom Nikic downgrades Allbirds (NASDAQ:BIRD) from Outperform to Neutral and announces $3 price target.

byBenzinga Newsdesk

March 6, 2023

1 minute read

Wedbush analyst Tom Nikic downgrades Allbirds (NASDAQ:BIRD) from Outperform to Neutral and announces $3 price target.

Baird Maintains Outperform on Taysha Gene Therapies, Lowers Price Target to $6

By Benzinga Newsdesk

February 1, 7:52 AM

Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and lowers the price target from $10 to $6.

TSHA

Roth Capital Downgrades Agrify to Neutral, Announces $1.5 Price Target

By Benzinga Newsdesk

August 16, 9:40 AM

Roth Capital analyst Scott Fortune downgrades Agrify (NASDAQ:AGFY) from Buy to Neutral and announces $1.5 price target.

AGFY

Benzinga’s Top Ratings Upgrades, Downgrades For January 4, 2023

By Benzinga Insights

January 4, 11:01 AM

Upgrades UBS upgraded the previous rating for Trane Technologies PLC (NYSE:TT) from Neutral to Buy. For the third…

ADSE

Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote In Favor Of NARCAN Nasal Spray, A Nonprescription Opioid Overdose Reversal Agent For Over-The-Counter Use

By Happy Mohamed

February 16, 1:35 AM

If approved by the FDA, NARCAN Nasal Spray will be the first 4 mg naloxone nasal spray switched from prescription status to over-the-counter use GAITHERSBURG, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) --

EBS

Wedbush Downgrades Allbirds to Neutral, Announces $3 Price Target

Related Posts

Baird Maintains Outperform on Taysha Gene Therapies, Lowers Price Target to $6

Roth Capital Downgrades Agrify to Neutral, Announces $1.5 Price Target

Benzinga’s Top Ratings Upgrades, Downgrades For January 4, 2023

Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote In Favor Of NARCAN Nasal Spray, A Nonprescription Opioid Overdose Reversal Agent For Over-The-Counter Use